Phase 3 findings could position the biotech’s therapy to become part of a “new standard” for SMA, its CEO said, while ...

Both had used methamphetamine before dying from an increasingly dangerous mix of soaring temperatures and stimulants. Meth is showing up more often as a factor in the deaths of people who died ...

The biotech company Scholar Rock reported Monday that its experimental ... paving the way for the likely approval of the drug. In a year-long Phase 3 trial, the company tested the drug, called ...

A Rock Island man with a history of drug trafficking convictions has been sentenced to 17½ years in federal prison after pleading guilty to conspiring to distribute meth and marijuana in the Quad ...

The lead singer of rock band The Alarm is in remission from an aggressive cancer thanks to an NHS drug trial. Mike Peters had been forced to cancel a US tour earlier this year after being ...

Scholar Rock contends its experimental drug for spinal muscular atrophy can achieve what none of the currently available therapies can do to treat this rare disease. After positive data from a ...

U.S. Customs and Border Protection (CBP) officers have seized more than $17 million worth of meth stashed inside a shipment of coconuts. On September 28, CBP officers at the Pharr International ...

(Reuters) -Scholar Rock's experimental drug achieved its main target in a late-stage trial for spinal muscular atrophy, the biotech company said on Monday, sending its shares soaring more than 300 ...

Policymakers in California embrace a proven but unorthodox treatment for meth and cocaine addiction: Give people gift cards ...

The crashing of waves, the somber recrimination of chilly charcoal clouds: for the young woman at the center of this story, ...

Oct 7 (Reuters) - Scholar Rock (SRRK.O), opens new tab said on Monday its drug met the main goal in a late-stage trial testing it on patients with a type of genetic neuromuscular disease.

12.5% on placebo. Scholar Rock Holding SRRK stock is trading higher on Monday after the company released topline results from the Phase 3 SAPPHIRE trial of apitegromab in spinal muscular atrophy.